Genotype-First Approach Identifies an Association between rs28374544/FOG2[sup.S657G] and Liver Disease through Alterations in mTORC1 Signaling

• Published in: Genes Vol. 15; no. 8
• Main Authors: Conlon, Donna M, Kanakala, Siri, Cherlin, Tess, Ko, Yi-An, Vitali, Cecilia, Gurunathan, Sharavana, Venkatesh, Rasika, Woerner, Jakob, Guare, Lindsay A, Biobank, Penn Medicine, Verma, Anurag, Verma, Shefali S, Guerraty, Marie A
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.08.2024
• Subjects: Analysis; Care and treatment; Genetic aspects; Genotype; Health aspects; Lipid metabolism; Liver diseases; Phenotype; Risk factors; United States
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes15081098

Metabolic dysfunction-associated Fatty Liver Disease (MAFLD) has emerged as one of the leading cardiometabolic diseases. Friend of GATA2 (FOG2) is a transcriptional co-regulator that has been shown to regulate hepatic lipid metabolism and accumulation. Using meta-analysis from several different biobank datasets, we identified a coding variant of FOG2 (rs28374544, A1969G, S657G) predominantly found in individuals of African ancestry (minor allele frequency~20%), which is associated with liver failure/cirrhosis phenotype and liver injury. To gain insight into potential pathways associated with this variant, we interrogated a previously published genomics dataset of 38 human induced pluripotent stem cell (iPSCs) lines differentiated into hepatocytes (iHeps). Using Differential Gene Expression Analysis and Gene Set Enrichment Analysis, we identified the mTORC1 pathway as differentially regulated between iHeps from individuals with and without the variant. Transient lipid-based transfections were performed on the human hepatoma cell line (Huh7) using wild-type FOG2 and FOG2[sup.S657G] and demonstrated that FOG2S[sup.657G] increased mTORC1 signaling, de novo lipogenesis, and cellular triglyceride synthesis and mass. In addition, we observed a significant downregulation of oxidative phosphorylation in FOG2[sup.S657G] cells in fatty acid-loaded cells but not untreated cells, suggesting that FOG2[sup.S657G] may also reduce fatty acid to promote lipid accumulation. Taken together, our multi-pronged approach suggests a model whereby the FOG2[sup.S657G] may promote MAFLD through mTORC1 activation, increased de novo lipogenesis, and lipid accumulation. Our results provide insights into the molecular mechanisms by which FOG2[sup.S657G] may affect the complex molecular landscape underlying MAFLD.